Skip to main content

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282, Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Gastroenterology

Awarded By

NGM Biopharmaceuticals, Inc.

Start Date

November 1, 2015

End Date

April 30, 2019
 

Administered By

Medicine, Gastroenterology

Awarded By

NGM Biopharmaceuticals, Inc.

Start Date

November 1, 2015

End Date

April 30, 2019